Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

Further Publications Dermatology

Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: Patient perspective data from the PROSE study

J Eur Acad Dermatol Venereol

da Silva N, Sommer R, Ortmann CE, Jagiello P, Bachhuber T, Augustin M

doi: 10.1111/jdv.17525

Psoriasis

Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: The PROSE study population

J Eur Acad Dermatol Venereol.

Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Rissler M, Gathmann S, Sieder C, Baeumer D, Orsenigo R

doi: 10.1111/jdv.16400.

Psoriasis

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

J Am Acad Dermatol.

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A

doi: 10.1016/j.jaad.2017.08.051.

COMMENTED

Psoriasis

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Am J Clin Dermatol.

Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA

doi: 10.1007/s40257-018-0396-z.

Psoriasis

Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study

Br J Dermatol.

Bissonnette R, Luger T, Thaçi D, Toth D, Messina I, You R, Guana A, Fox T, Papavassilis C, Gilloteau I, Mrowietz U

doi: 10.1111/bjd.15706.

Psoriasis

Secukinumab for patients failing previous TNFα-inhibitor therapy: results of a randomised open-label study (Signature)

Br J Dermatol.

Warren RB, Barker J, Finlay AY, Burden AD, Kirby B, Armendariz Y, Williams R, Hatchard C, Khare S, Griffiths CEM

doi: 10.1111/bjd.18623.

Psoriasis

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)

J Eur Acad Dermatol Venereol.

Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A, Ahmad K, Paguet B, Xia S, Muscianisi E, Lebwohl M

doi: 10.1111/jdv.16558.

Psoriatic Arthritis

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Arthritis Res Ther.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group

doi: 10.1186/s13075-018-1773-y.

Psoriasis

Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?

J Eur Acad Dermatol Venereol.

Langenbruch A, Radtke MA, Gutknecht M, Augustin M

doi: 10.1111/jdv.15226.

Related content

Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: Patient perspective data from the PROSE study

Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: The PROSE study population

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Secukinumab Sustains Good Efficacy and Favourable Safety in Moderate to Severe Psoriasis up to 3 Years of Treatment: Results from A Double-Blind Extension Study

Secukinumab for patients failing previous TNFα-inhibitor therapy: results of a randomised open-label study (Signature)

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?